Catalyst Pharmaceuticals (CPRX) Return on Capital Employed (2011 - 2026)

Catalyst Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 26.94% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 316.0% year-over-year to 26.94%; the trailing twelve-month figure through Mar 2026 stood at 26.94% (down 316.0% YoY), and the FY2025 full-year result was 31.04%, down 509.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 26.94%, down from 27.7% in the prior quarter.
• The five-year high for Return on Capital Employed was 37.05% in Q2 2023, with the low at 14.7% in Q2 2024.
• Historically, Return on Capital Employed has averaged 27.81% across 5 years, with a median of 28.24% in 2024.
• Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 2235 bps — and 2025, when it jumped 1472 bps.
• Catalyst Pharmaceuticals' Return on Capital Employed stood at 34.31% in 2022, then slumped by 31 bps to 23.75% in 2023, then advanced by 19 bps to 28.24% in 2024, then decreased by 2 bps to 27.7% in 2025, then declined by 3 bps to 26.94% in 2026.
• The last three Return on Capital Employed figures came in at 26.94% (Q1 2026), 27.7% (Q4 2025), and 29.31% (Q3 2025), per Business Quant data.